Literature DB >> 24101119

Appropriate chemotherapy dosing in obese patients with cancer.

Gary H Lyman1, Alex Sparreboom.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24101119     DOI： 10.1038/nrclinonc.2013.108-c2

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

Review 1.  Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.

Authors:  K C Hourdequin; W L Schpero; D R McKenna; B L Piazik; R J Larson
Journal:  Ann Oncol       Date:  2013-08-21       Impact factor: 32.976

2.  Sarcopenia and chemotherapy dosing in obese patients.

Authors:  Alessandro Laviano; Serena Rianda; Filippo Rossi Fanelli
Journal:  Nat Rev Clin Oncol       Date:  2013-10-08       Impact factor: 66.675

Review 3.  Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Authors:  Jennifer J Griggs; Pamela B Mangu; Holly Anderson; Edward P Balaban; James J Dignam; William M Hryniuk; Vicki A Morrison; T May Pini; Carolyn D Runowicz; Gary L Rosner; Michelle Shayne; Alex Sparreboom; Lara E Sucheston; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

Review 4.  Sarcopenic obesity: A Critical appraisal of the current evidence.

Authors:  C M M Prado; J C K Wells; S R Smith; B C M Stephan; M Siervo
Journal:  Clin Nutr       Date:  2012-07-17       Impact factor: 7.324

5.  Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.

Authors:  Candice M Wenzell; Erika M Gallagher; Marc Earl; Jun-Yen Yeh; Karissa N Kusick; Anjali S Advani; Matt E Kalaycio; Sudipto Mukherjee; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Am J Hematol       Date:  2013-08-30       Impact factor: 10.047

Review 6.  Chemotherapy dosing in overweight and obese patients with cancer.

Authors:  Gary H Lyman; Alex Sparreboom
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

Review 7.  Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses.

Authors:  Vickie Baracos; Seyyed Mohammad Reza Kazemi-Bajestani
Journal:  Int J Biochem Cell Biol       Date:  2013-06-29       Impact factor: 5.085

8.  Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Authors:  Olivier Mir; Romain Coriat; Benoit Blanchet; Jean-Philippe Durand; Pascaline Boudou-Rouquette; Judith Michels; Stanislas Ropert; Michel Vidal; Stanislas Pol; Stanislas Chaussade; François Goldwasser
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240
  8 in total
  3 in total

1.  Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).

Authors:  Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge
Journal:  Breast Cancer Res Treat       Date:  2016-07-22       Impact factor: 4.872

2.  The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.

Authors:  H Ian Robins; Jens Eickhoff; Mark R Gilbert; Terri S Armstrong; Wenyin Shi; John F De Groot; Christopher J Schultz; Grant K Hunter; Egils Valeinis; Mack Roach; Emad F Youssef; Luis Souhami; Steve P Howard; Frank S Lieberman; James G Herman; Peixin Zhang; Minesh P Mehta
Journal:  Neurooncol Pract       Date:  2019-04-06

3.  Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.

Authors:  Gargi S Patel; Shahid Ullah; Carol Beeke; Paul Hakendorf; Robert Padbury; Timothy J Price; Christos S Karapetis
Journal:  Cancer Med       Date:  2015-07-25       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.